首页> 外文期刊>The Open Neuropsychopharmacology Journal >Metabolic Effects of Olanzapine and Quetiapine: A Six-Week Randomized,Single Blind, Controlled Study
【24h】

Metabolic Effects of Olanzapine and Quetiapine: A Six-Week Randomized,Single Blind, Controlled Study

机译:奥氮平和喹硫平的代谢作用:六周随机,单盲,对照研究

获取原文
       

摘要

The objective of this study is to compare the course of metabolic effects of olanzapine and quetiapine, twoatypical antipsychotics with similar structure and receptor binding affinities but clinically observed different metabolic effects.This 6 week, single blind, randomized, controlled study was carried out during a structured treatment protocol in afemale inpatient service, thus enabled to control effects of energy expenditure and other life style related factors. Subjectswere randomly assigned into olanzapine (n=15) and quetiapine (n=15) groups. Weight and calorie intake (CI) were measureddaily. Symptom severity and serum leptin levels (SLL) were measured biweekly. Serum lipids were measured atbaseline and 6th week. Olanzapine treatment was associated with more severe weight gain (F=11.2, p<0.01), increase inCI (F=8.1, p<0.01) and a more disturbed lipid profile than quetiapine. The course of SLL were similar between the groups(F=1.39, p=0.26). Weight, CI and SLL changed in a similar pattern within the groups but the patterns were different foreach drug, suggesting that the two drugs have different mechanisms for weight change. The explanation probably involvesdifferent affinities for 5HT2C receptors leading to different patterns of CI which we propose as possible targets of interventionto manage antipsychotic induced weight gain.
机译:本研究的目的是比较奥氮平和喹硫平,具有结构相似和受体结合亲和力但临床观察到不同代谢作用的两种非典型抗精神病药的代谢过程。本研究为期6周,是在一次单盲,随机,对照研究中进行的。女性住院服务中的结构化治疗方案,从而能够控制能量消耗和其他生活方式相关因素的影响。将受试者随机分为奥氮平(n = 15)和喹硫平(n = 15)组。每天测量体重和卡路里摄入量(CI)。每两周测量一次症状严重程度和血清瘦素水平(SLL)。在基线和第6周测量血清脂质。与喹硫平相比,奥氮平治疗与体重增加更为严重(F = 11.2,p <0.01),CI升高(F = 8.1,p <0.01)和脂质分布紊乱有关。各组之间的SLL病程相似(F = 1.39,p = 0.26)。各组的体重,CI和SLL变化相似,但每种药物的变化模式不同,这表明两种药物的体重变化机制不同。这种解释可能涉及5HT2C受体的不同亲和力,导致不同的CI模式,我们建议将其作为管理抗精神病药物引起的体重增加的干预目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号